glp 1 and norethindrone AUROVELA (norethindrone acetate/ethinyl estradiol) AUROVELA (norethindrone acetate/ethinyl estradiol)

Combatting the opioid overdose epidemic has some good news emerging from the medicines sector, with per capita prescribing of opioids down 67% since its apex in 2011

market.

A large Cleveland Clinic study has found that people with obesity and Type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

Electronic databases including PubMed, Embase, and Web of Science were searched from inception until August 2025 using keywords such as GLP-1 receptor agonist, diabetic retinopathy, glaucoma, age-related macular degeneration, ocular disease, and neuroprotection. The search focused on identifying preclinical studies, large-scale retrospective cohort studies, and post-hoc analyses of major clinical trials that evaluated the utility and potential mechanisms of GLP-1RAs in ophthalmic diseases

Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression

RESULTS: Following the breakfast, GLP-1 infusion suppressed ratings of hunger and prospective food consumption (P<0.05), whereas all other subjective ratings and ad libitum energy intake were unaffected